Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry

November 30, 2020

Popp, C., Schramm, P., Wagner, R., et al.

bioRxiv 2020, doi: 10.1101/2020.11.30.403873

Abstract

Vaccines are on the front line-of-defense against infectious diseases, ranging from threats we are familiar with, including polio, tuberculosis, or HIV, to novel and emerging threats such as SARS-CoV-2. Successful development of new protein-based vaccines requires sophisticated and efficient development of storage and formulation conditions. Here we demonstrate the combined power of 2bind’s sophisticated buffer matrix FORMOscreen® and NanoTemper Technologies’ novel Prometheus Panta high-throughput Dynamic Light Scattering/Nano Differential Scanning Fluorimetry instrument. We show that this combination can comprehensively improve critical biophysical parameters for the HIV-1 vaccine BG505-SOSIP and find the optimal formulation condition with unmatched efficiency.

View Publication

Topics: Prometheus, nanoDSF, DLS, Biologics, Publications

Previous
Your guide to efficiently develop antibody-based therapeutics
Your guide to efficiently develop antibody-based therapeutics

How to measure stability, why it's important, and where it belongs in the workflow

Up next
Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy
Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy

Want to see more
biologics content?

Explore resources